|
CDCA7L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.17059997648295E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.44870000007691E-07 |
| Normal-vs-Stage2 |
2.957600E-03 |
| Normal-vs-Stage3 |
3.17190000043155E-07 |
| Normal-vs-Stage4 |
3.2462999954852E-08 |
| Stage1-vs-Stage2 |
5.616000E-01 |
| Stage1-vs-Stage3 |
1.064610E-01 |
| Stage1-vs-Stage4 |
9.138800E-03 |
| Stage2-vs-Stage3 |
1.478050E-01 |
| Stage2-vs-Stage4 |
2.736000E-02 |
| Stage3-vs-Stage4 |
2.265400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.78439999998226E-07 |
| Normal-vs-AfricanAmerican |
9.259400E-03 |
| Normal-vs-Asian |
1.806390E-04 |
| Caucasian-vs-AfricanAmerican |
2.862600E-01 |
| Caucasian-vs-Asian |
4.465000E-01 |
| AfricanAmerican-vs-Asian |
6.808000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.40070000001991E-07 |
| Normal-vs-Female |
1.10910000072906E-08 |
| Male-vs-Female |
8.179800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.01370000005208E-06 |
| Normal-vs-Age(41-60Yrs) |
5.28339999528171E-08 |
| Normal-vs-Age(61-80Yrs) |
5.94620000016199E-07 |
| Normal-vs-Age(81-100Yrs) |
3.458500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.148000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.106400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.441400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.158000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.981600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.563000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.76069999999951E-05 |
| Classical-VS-Follicular |
1.23279999997283E-06 |
| Classical-VS-Other |
8.858600E-01 |
| Classical-VS-Normal |
1.99070000039825E-07 |
| Tall-VS-Follicular |
1.19000365117472E-11 |
| Tall-VS-Other |
2.098800E-01 |
| Tall-VS-Normal |
1.1670997501767E-11 |
| Follicular-VS-Other |
1.605600E-01 |
| Follicular-VS-Normal |
1.377620E-01 |
| Other-VS-Normal |
4.538500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.57210000000441E-05 |
| Normal-vs-N1 |
3.59349999756731E-08 |
| N0-vs-N1 |
2.881100E-03 |
|
|
